FA
CTMX icon

Forefront Analytics’s CytomX Therapeutics CTMX Stock Holding History

Forefront Analytics’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58.6K Sell
12,476
-6,223
-33% -$31.6K 0.05% 38
2025
Q4 		$79.7K Buy
18,699
+590
+3% +$2.24K 0.07% 39
2025
Q3 		$57.8K Sell
18,109
-9,589
-35% -$21.6K 0.06% 43
2025
Q2 		$62.9K Sell
27,698
-72,372
-72% -$117K 0.07% 40
2025
Q1 		$63.1K Buy
100,070
+35,811
+56% +$27.8K 0.07% 43
2024
Q4 		$66.2K Buy
64,259
+4,499
+8% +$4.84K 0.03% 64
2024
Q3 		$70.5K Sell
59,760
-4,305
-7% -$5.47K 0.03% 66
2024
Q2 		$78.2K Buy
64,065
+43,176
+207% +$85.9K 0.04% 67
2024
Q1 		$45.5K Sell
20,889
-9,957
-32% -$18.4K 0.02% 67
2023
Q4 		$47.8K Sell
30,846
-18,575
-38% -$24.4K 0.02% 67
2023
Q3 		$63.8K Sell
49,421
-175
-0.4% -$276 0.04% 61
2023
Q2 		$85.3K Buy
49,596
+23,184
+88% +$38.5K 0.05% 59
2023
Q1 		$39.9K Buy
26,412
+1,625
+7% +$3.67K 0.02% 77
2022
Q4 		$39.7K Sell
24,787
-23,082
-48% -$34.1K 0.02% 71
2022
Q3 		$71K Buy
47,869
+11,950
+33% +$18.4K 0.04% 57
2022
Q2 		$67K Buy
35,919
+21,275
+145% +$40.7K 0.03% 58
2022
Q1 		$40K Buy
14,644
+900
+7% +$3.46K 0.01% 68
2021
Q4 		$62K Buy
13,744
+350
+3% +$2.05K 0.02% 61
2021
Q3 		$68K Buy
+13,394
New +$71.7K 0.02% 63

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Forefront Analytics's CTMX Position: Q1 2026 in Review

Forefront Analytics reduced its CytomX Therapeutics (CTMX) stake by 33% in Q1 2026, selling an estimated $31.6K and leaving 12,476 shares worth $58.6K. The position accounts for 0.05% of the portfolio, ranked #38.

Forefront Analytics first reported a position in CTMX in Q3 2021 and has held it in 19 quarters since. The position peaked at $85.3K in Q2 2023. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Forefront Analytics held 12,476 shares of CytomX Therapeutics worth $58.6K as of Q1 2026.
  • Forefront Analytics sold 6,223 CytomX Therapeutics shares in Q1 2026, an estimated $31.6K.
  • CytomX Therapeutics made up 0.05% of Forefront Analytics's portfolio in Q1 2026, its #38 holding.
  • Forefront Analytics first reported a position in CytomX Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • Forefront Analytics's CytomX Therapeutics position peaked at $85.3K in Q2 2023.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Forefront Analytics's 13F filing for Q1 2026, filed 13 May 2026.